Ex-Gilead R&D chief Bischofberger starts over as CEO of Kronos Bio; Sue Mahony steps down from Lilly Oncology
→ After spending the past 30 years before the R&D mast at Gilead, ex-research chief Norbert Bischofberger is starting over from scratch. This morning, just a few weeks after his formal departure from the head job at one of the world’s top 15 drug research organizations, Bischofberger is jumping on board at an upstart biotech with just four full-time staffers. He’s chipped in to an $18 million seed round — roughly 1/200th the size of this year’s R&D budget at Gilead — to launch Kronos Bio. The biotech in-licensed a platform technology out of the lab of MIT professor Angela Koehler focused on modulating transcription factors in cancer, with two preclinical programs focused on MYC and the red-hot androgen receptor target.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
